Epidemiologie und Kosten von Asthma 
bronchiale und chronischer Bronchitis in Deutschland

Weissflog, D; Matthys, H; Virchow, Jr Jc

doi:10.1055/s-2001-15705

Cited by 29 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Asthma therefore poses a significant burden of disease for the affected patients. The annual mean sick leave days in employed asthma patients are around 23 days [6]. In Germany the total direct costs of asthma were measured to be about 2.35 billion euro; the costs for sick leave days caused by asthma were estimated to be 242 million euro for the year 2006 [7].…”

Section: Introductionmentioning

confidence: 99%

Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthma

Reinhold

Ostermann

Thum-Oltmer³

et al. 2013

Clinical & Translational All

View full text Add to dashboard Cite

BackgroundSubcutaneous specific immunotherapy (SCIT) is an effective treatment attenuating the progression of allergic asthma. To date, there is a lack of studies investigating the economic consequences of SCIT on health care expenditures.MethodsA health-economic piggy-back analysis of SCIT was conducted based on a RCT that enrolled 65 children and adolescents with allergic asthma. Patients were allocated into two groups: A group receiving SCIT with a high-dose hypoallergenic house dust mite preparation plus asthma medication and a control group receiving only asthma medication. For both groups asthma control was achieved before the start of the SCIT treatment and was maintained during the study. Both, costs and cost-effectiveness of SCIT with the high-dose hypoallergenic house dust mite preparation were investigated based on total medication costs, incremental medication costs and treatment effects (measured as lung function), respectively. A bootstrap analysis was performed to validate the results.ResultsA steady decline in medication costs could be observed in the SCIT group one year after treatment start compared to the control group. This cost trend became statistically significant 3 years after SCIT started. The calculated potential savings in the SCIT group correlated with an improved lung function. The distribution of the bootstrap results revealed that the probability of SCIT having a superior effectiveness compared to the control group is around 90%.ConclusionSCIT with a high-dose hypoallergenic preparation received by children and adolescents suffering from mite induced allergic asthma reduces the allergic medication intake and has cost-saving effects. Additional costs associated with SCIT may be completely compensated by drug cost savings 4 years after end of SCIT. Additionally, SCIT is superior compared to routine care as measured by the lung function that improved in SCIT-treated patients. Trial registration: (EudraCT no. 2004 – 003892 – 35).

show abstract

Section: Introductionmentioning

confidence: 99%

Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthma

Reinhold

Ostermann

Thum-Oltmer³

et al. 2013

Clinical & Translational All

View full text Add to dashboard Cite

show abstract

“…In industrialized countries, the costs of treatment AB reach 1-2% of total medical costs (Karmaus et al, 2013). However, is some countries can reach even up to 55% (Weissflog et al, 2001). Canadian study found 20.5% of const is attributable to inpatient care, 47.8% to outpatient care and 31.5% to medication (Sadatsafavi et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Asthma Bronchiale in the Czech Republic and its Economic Burden

Josef¹,

Vlastimil²,

Lucie³

et al. 2016

American Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Dies hat bereits die AIRE-Studie [3] mithilfe einer Befragung von 2803 Asthmapatienten dargestellt: Nur 5 % der Befragten wiesen eine vollständige Asthmakontrolle, wie in den GINA-Leitlinien definiert, auf [2]. Die Versorgung von Asthmapatienten in Deutschland ist vergleichbar unbefriedigend, wie mehrere Studien mithilfe von Arzneimittel-Routinedaten belegen [4][5][6][7][8][9]. Die Zahl der Publikationen aus Deutschland, die die Versorgung von Asthmapatienten in Deutschland thematisieren, ist gering [10].…”

Section: Abstract !unclassified

“…Die Zahl der Publikationen aus Deutschland, die die Versorgung von Asthmapatienten in Deutschland thematisieren, ist gering [10]. Weissflog et al [9] untersuchten die Kosten der Erkrankungen Asthma und chronische Bronchitis anhand von Sekundärdaten von Regierungsinstitutionen und pharmazeutischer Industrie. Größter Posten der direkten Kosten für Asthma bronchiale waren die ambulanten Arzneimittelkosten, gefolgt von den Kosten für Krankenhausaufenthalte.…”

Section: Abstract !unclassified

Versorgung von Asthmapatienten mit Kombinationstherapie aus ICS und LABA – Eine GKV-Daten-Analyse

Friedel

Virchow

2014

Pneumologie

View full text Add to dashboard Cite

Zusammenfassung Die Untersuchung stellt anhand der Abrechnungsdaten von Betriebskrankenkassen die Versorgung von Patienten mit Asthma bronchiale mit einer fixen Kombinationstherapie (drei verschiedene Wirkstoffkombinationen) dar. Die identifizierten Patienten wurden nach ihrer Kombinationstherapie, ihrem Therapieverlauf und der Anzahl der m?glichen Therapietage mit zwei H?ben kategorisiert. Die Effekte der Therapiegruppe, des Therapieverlaufs sowie der Anzahl der Tage mit zwei H?ben auf die Dauer und die Kosten der Krankenhausaufenthalte wurden untersucht. 47,9?% der 16?312 Versicherten waren ?nur? f?r maximal 6 von 24 Monaten mit zwei H?ben einer Fixkombination aus ICS und LABA pro Tag versorgt. 8,3?% waren f?r den gesamten Untersuchungszeitraum mit mindestens 2 H?ben pro Tag ausgestattet. Die Ergebnisse k?nnen die in anderen Studien gefundene unzureichende Asthmakontrolle erkl?ren und als Grundlage f?r weitere Untersuchungen der Versorgungsrealit?t dienen. ?ber die Gr?nde f?r die Unterversorgung muss spekuliert werden. Als Handlungsempfehlung f?r die Praxis bleibt, Ma?nahmen zur Messung und Steuerung von Adh?renz sowie den Grad der Leitlinienumsetzung zu hinterfragen.

show abstract

Epidemiologie und Kosten von Asthma bronchiale und chronischer Bronchitis in Deutschland

Abstract: The data suggest that therapeutic progress and cessation of smoking can provide distinctive savings of direct costs and even more of indirect costs of AB and CB.

Cited by 29 publications

References 3 publications

Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthma

Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthma

Prevalence of Asthma Bronchiale in the Czech Republic and its Economic Burden

Versorgung von Asthmapatienten mit Kombinationstherapie aus ICS und LABA – Eine GKV-Daten-Analyse

Contact Info

Product

Resources

About